Histiocytic Disorders

  • Oussama Abla
  • Gritta Janka

Table of contents

  1. Front Matter
    Pages i-xii
  2. Pathology of Histiocytic Disorders

    1. Front Matter
      Pages 1-1
  3. Langerhans Cell Histiocytosis (LCH)

    1. Front Matter
      Pages 51-51
    2. Barrett J. Rollins
      Pages 53-71
    3. Milen Minkov, Jennifer Picarsic, Karoly Lakatos
      Pages 87-101
    4. Carlos Rodriguez-Galindo, Cor van den Bos
      Pages 103-118
    5. Oussama Abla, Carlos Rodriguez-Galindo, Paul Veys
      Pages 119-137
    6. Michael Girschikofsky, Abdellatif Tazi
      Pages 139-153
    7. Vasanta Nanduri, Lilibeth R. Torno, Riccardo Haupt
      Pages 155-170
  4. Hemophagocytic Lymphohistiocytosis (HLH)

    1. Front Matter
      Pages 171-171
    2. J. Pachlopnik Schmid, Benjamin Volkmer, Stephan Ehl
      Pages 173-187
    3. AnnaCarin Horne, Karin Beutel
      Pages 189-196
    4. Geneviève de Saint Basile, Despina Moshous, Alain Fischer
      Pages 197-214
    5. Kai Lehmberg, Fumihiro Ochi, Kim E. Nichols, Eiichi Ishii
      Pages 215-231
    6. Alexei A. Grom, AnnaCarin Horne, Fabrizio De Benedetti
      Pages 233-246
    7. Jan-Inge Henter, Rebecca A Marsh, Tatiana von Bahr Greenwood
      Pages 247-263
    8. Paul La Rosée, Rafal Machowicz
      Pages 275-290

About this book

Introduction

This volume provides a comprehensive and world-class review of the field of histiocytic neoplasms and hemophagocytic lymphohistiocytosis (HLH). It reviews all the advances in the field of histiocytoses during the last ten years, particularly with regards to the genomic findings in LCH and other histiocytic neoplasms and the new suggested classification of the histiocytic disorders. Additionally, it features a state-of-the art update on the most recent treatment strategies for LCH, including the results of the last LCH-III international trial, salvage therapies such as reduced-intensity conditioning (RIC) stem cell transplant (SCT), and targeted therapies with BRAF and MEK inhibitors, as well as the challenging cases of CNS-neurodegenerative LCH and its therapeutic perspectives. For primary and secondary HLH the book updates the most recent genetic and pathophysiological findings, including macrophage-activation syndrome (MAS), and includes a special chapter on HLH in adults. Treatment chapters encompass therapy for newly diagnosed HLH and refractory disease as well as stem-cell transplantation and novel therapies. The text also highlights the most recent advances in the treatment of the uncommon histiocytic disorders, such as Erdheim-Chester disease (ECD), Juvenile xanthogranuloma (JXG) and JXG-like conditions, Rosai-Dorfman disease (RDD), and the very rare malignant histiocytoses.

Written by international experts in the field, Histiocytic Disorders is a valuable resource for clinicians, researchers, fellows and residents who are interested in or manage histiocytic disorders in children and adults.

Keywords

langerhans cell Histiocytosis hemophagocytic lymphohistiocytosis macrophage activation syndrome JXG family Erdheim-Chester disease Rosai-Dorfman disease

Editors and affiliations

  • Oussama Abla
    • 1
  • Gritta Janka
    • 2
  1. 1.University of TorontoThe Hospital for Sick ChildrenTorontoCanada
  2. 2.Pediatric Hematology and OncologyUniversity Medical Center Hamburg EppendorfHamburgGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-59632-7
  • Copyright Information Springer International Publishing AG 2018
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-59631-0
  • Online ISBN 978-3-319-59632-7
  • About this book